DAY 4: Wednesday, September 24, 2025

Program subject to change.

07:00 - 17:00

Registration Open

07:15 - 08:15

Industry-Sponsored Symposia with Breakfast

08:30 - 10:00

Concurrent Symposia 7 & 8

Symposium 7: Non-CYP450 Enzymes in Drug Metabolism and Drug Design

Co-Chairs: Bhagwat Prasad, Cincinnati Children's Hospital, USA; Mike Zientek, Treeline Biosciences, USA

  • This session brings together experts from academia and industry to explore the expanding role of non-CYP enzymes in drug development. Topics include the mechanism and metabolism of diverse drug modalities through non-CYP pathways, the physiological and pathological roles of carboxylesterase and arylacetamide deacetylase in drug metabolism, and the involvement of methyltransferases in metabolizing therapeutic agents. The session also highlights the strategic use of non-CYP enzymes in the design and development of drugs and prodrugs, offering insights into their emerging importance for innovative therapeutics.

  • Role of non-CYP enzymes in metabolism of new drug modalities
    Deepak Ahire, Gilead Sciences, USA

  • Role of carboxylesterase and arylacetamide deacetylase in drug metabolism, physiology, and pathology
    Tatsuki Fukami, Kanazawa Unviersity, Japan

  • Non-CYP enzymes in drug and prodrug design and development
    Rana Rais, Johns Hopkins, USA

Symposium 8: Humanized Animal Models

Co-chairs: Yukio Kato, Kanazawa University, Japan; Chitra Saran, Merck, USA

  • This session will highlight the importance of humanized animal models to address challenges related to species differences in drug or biomarker disposition due to metabolic enzymes and transporters. Topics covered will include the application of humanized rodent models for CYP or UGT enzymes and transporters, with a focus on enhancing the PK and DDI prediction for drugs, as well as improving the clinical translation of biomarkers.

  • Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism
    Kevin Read, University of Dundee, UK

  • Pharmacogenomics, drug metabolism and pharmacokinetic study using chimeric NOG-TKm30 mice with humanized livers
    Hiroshi Yamazaki, Showa Pharmaceutical University, Japan

  • The humanized OATP1B rat model
    Jocelyn Yabut, Merck, USA

10:30 - 12:30

Concurrent Symposia 9 & 10

Symposium 9: DMET in Toxicology

Co-chairs: Eric Chan, National University of Singapore, Singapore; Albert Li, Discovery Life Sciences, USA

  • The symposium will provide an up-to-date review of the roles of bile acid transporters, drug metabolizing enzymes on drug toxicity,  as well as experimental approaches and clinical evidence to identify the roles of specific drug metabolizing enzyme pathways responsible for the manifestation of adverse effects.

  • Bile acid transport and drug toxicity
    Chitra Saran, Merck, USA

  • UGT inhibition and DILI potential
    Yvonne Will, Crinetics Pharmaceuticals, USA

  • Cytotoxic reactive metabolite formation as a key determinant of idiosyncratic liver toxicity
    Albert Li, Washington State University, USA

  • Implications of CYP2J2 in drug-induced cardiac adverse effects
    Eric Chan, National University of Singapore, Singapore

Symposium10: Difficult-to-study and understudied? Model informed evidence with translational power

Co-chairs: Maria Posada, Eli Lilly, USA; Daniel Scotcher, University of Manchester, UK

  • This session will highlight new advances in applying modelling and simulation for addressing challenges that are not readily resolved through experimental approaches alone. The speakers will illustrate the utility of using mechanistic and translational modelling to support drug discovery and development, including for understudied populations.

  • Transforming the Development of Targeted Protein Degraders: The Translational Power of PK/PD Modeling beyond the Human Dose Projection
    Robin Haid, Bayer, Germany

  • Establishing a physiologically-based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates
    Daniel Scotcher, University of Manchester, UK

  • Model-informed optimisation of drug dosing in pregnancy
    Saskia de Wildt, Radboud University Medical Center, Netherlands

12:00 - 15:00

Lunch/Exhibits/Posters Viewing/Supplier Showcase

15:30 - 17:00

Symposia 11: Drug Discovery Tales

Co-chairs: Li Di, Recursion Pharmaceuticals, USA; Raju Subramanian, Gilead, USA

  • This session discusses DMPK learnings from recently approved successful drugs in neuroscience, endocrinology and anti-infectives. Topics that will be covered include challenges on predicting prodrug conversions in humans from in vitro and preclinical species, necessity of ADME package with full 14C assessment to support registration, and strategies on developing long-acting agents.

  • Expanding the Repertoire for “Large Small Molecules”: Challenges in developing an oral prodrug of the BCL-2 inhibitor Venetoclax
    Gary Jenkins, AbbVie, USA

  • Development Considerations for Tirzepatide: Is it a Small Molecule or a Large Molecule?
    Jennifer Martin, Lilly, USA

  • The Story of Lenacapavir, a First-in-Class Long-Acting HIV Capsid Inhibitor, From Discovery to Clinical Development
    Raju Subramanian, Gilead, USA

17:00 - 17:15

Closing Session